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A b s t r A c t
bAckround: Continuous infusion of midazolam is related to prolonged activity and 
delayed awakening in the critically ill. Serum midazolam levels can be helpful in dif-
ferentiating residual benzodiazepine activity from other causes of impaired level of 
consciousness (LOC). Although drug levels can also be measured in the urine, the 
relationship between serum and urine levels with the observed LOC has not been 
studied in clinical practice. 
objectives: To investigate the correlation between serum and urine midazolam lev-
els in the critically ill and their correlation with the observed level of consciousness 
estimated with the Glasgow Coma Scale (GCS) and the Full Outline of UnRespon-
siveness Score (FOUR score). 
PAtients And Methods:This is a prospective observational study involving patients 
admitted to a 30 bed General Intensive Care Unit (ICU), who were intubated and me-
chanically ventilated, with GCS prior to intubation >8. Midazolam infusion was dis-
continued for at least 12 hours before sampling. Serum and urine sampling to measure 
midazolam levels and clinical evaluation to calculate the GCS and FOUR score were 
done simultaneously
results: Twenty patients fulfilled the inclusion criteria and participated in the study. 
Serum midazolam levels correlated moderately with the GCS (R =-0.496, p=0.026) 
and better with the FOUR score (R =-0.685, p=0.001), but did not correlate with 
measured levels in the urine (R =-0.029 p=0.904). 
conclusions: After discontinuation of midazolam sedation, the LOC correlate sig-
nificantly with the drug levels in the serum. Urine midazolam levels do not correlate 
with those measured in the serum or with the observed LOC.
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i n t r o d u c t i o n
Midazolam Hydrochloride was first synthesised by Fryer 
and walser in 1976. It is a short-acting water-soluble ben-
zodiazepine drug with an elimination half life of 2.3 - 2.5 
hours that acts on GABA- (γ-amino butyric acid) associated 
benzodiazepine receptors. It has hypnotic, anticonvulsant, 
muscle-relaxant and anxiolytic properties and anterograde 
amnesic effects.1 In clinical practice, it is used for the induc-
tion of anesthesia, sedation and the treatment of generalised 
seizures or status epilepticus.2,3 Due to its chemical structure 
it has rapid absorption, distribution rate and metabolism. Fol-
lowing intravenous injection the plasma concentration of the 
drug decreases to 10% within 2 hours. Midazolam is bound 
extensively to plasma proteins and only the unbound drug 
is pharmacologically active. Once administered, it becomes 
highly lipophilic and has enhanced penetration into the central 
nervous system (CNS). It is oxidised by the liver faster than 
other benzodiazepines and, consequently, has a shorter dura-
tion of action. Its hepatic metabolites, 1′-hydroxymidazolam 
(1′-OHMDz) and, to a smaller extent, 4-hydroxymidazolam 
(4-OHMDz) and 1,4-dihydroxymidazolam, are pharmacologi-
cally active and are conjugated and then excreted as glucuro-
nides in the urine.4,5
Midazolam is the benzodiazepine of choice for sedation in 
the critically ill6 because of its fast onset and short duration of 
action, its minimal cardiovascular and respiratory effects and the 
induction of retrograde amnesia. Nevertheless, it has significant 
side effects, the most notable of which is residual sedation after 
cessation of the drug following prolonged continuous infusion.7 
Residual sedation mechanisms include fat absorption and re-
distribution of the drug from the fat tissue to the circulation, 
delayed metabolism and excretion in case of renal and hepatic 
failure and P450 inhibition by other co-administered drugs. In 
the critically ill, residual sedation may be difficult to differentiate 
clinically from other causes of decreased level of consciousness 
(LOC) such as non-convulsive status epilepticus, encephalopa-
thy, CNS infections, cerebrovascular disease and post anoxic 
injury.8,9 The need to rule out these entities may result in overuse 
of imaging and neurophysiological studies. 
Serum benzodiazepine levels can be helpful in differentiat-
ing residual drug activity from other causes of impaired LOC.10 
Urine samples have also been used mainly in the emergency 
and in the palliative care setting.11 This study aims at identify-
ing if urine midazolam levels are correlated with serum mida-
zolam levels and with the level of consciousness in critically ill 
patients. Based on the drug’s complex pharmacokinetics we 
hypothesize that serum levels have a better correlation with 
the LOC as measured by the GCS and the FOUR score than 
the urine levels, and that there is a weak or no correlation 
between the serum and the urine levels of the drug. 
M e t h o d s
s e t t i n g
A 30 bed University General Intensive Care Unit. The 
unit admits unselected medical and surgical patients includ-
ing trauma.
PA t i e n t s
The inclusion criteria for the study were patient age >18, 
prior sedation and mechanical ventilation with Glasgow Coma 
Scale (GCS) prior to intubation >8. Exclusion criteria were 
admission to ICU with coma, a diagnosis relevant to acute 
neurological injury, pregnancy and any contraindication to 
the cessation of sedation, including severe respiratory failure 
and evidence or suspicion of increased intracranial pressure. 
Patients that received fentanyl for analgesia were also excluded 
from the study because this drug can have prolonged action 
in ICU patients.12
c l i n i c A l  A s s e s s M e n t
After the initial assessment for inclusion in the study, mi-
dazolam infusion was discontinued for at least 12 hours. The 
level of consciousness was subsequently assessed with the GCS 
and the Full Outline of UnResponsiveness (FOUR) score.13,14 
In cases were other sedatives were used after the discontinua-
tion of midazolam, i.e. propofol or remifentanyl, all sedatives 
were discontinued for at least 3 hours prior to the clinical 
assessment. Other data gathered were: age, sex, weight and 
height, reason for admission to intensive care, renal function 
tests and the application of renal replacement therapy. The 
Sequential Organ Failure Assessment (SOFA) score was also 
calculated for all patients.15
M i d A z o l A M  M e A s u r e M e n t s
Serum midazolam measurements were performed on the 
Cobas Integra 400 system (Roche), which is suitable for semi-
quantitative detection of benzodiazepines in the serum. Urine 
midazolam levels were measured with the Cobas C501 system 
(Roche), which is suitable for semiquantitative detection of 
benzodiazepines in human urine. 
e t h i c s
The Scientific and Ethics committee of Evangelismos 
hospital approved the study protocol. Informed consent from 
the patient’s next of kin was obtained for all study participants.
s t A t i s t i c s
The maximum, minimum and median values were used 
for descriptive statistics. Correlation between serum and urine 
midazolam values, as well as correlation with the LOC scales 
was measured with the Pearson’s coefficient. 
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r e s u l t s
During the study period 28 patients were evaluated for par-
ticipation. Eight of these were excluded. Two did not receive 
benzodiazepines, two did not produce urine and a consent 
form could not be obtained in 4 cases. Twenty patients were 
finally included in the study. The demographics and the clinical 
characteristics of the study population are presented in Table 
1. Six patients were on CVVHDF (Continuous Veno-Venous 
Haemodiafiltration) during the study period and three of them 
were on CVVHD at sampling time. Two additional patients 
fulfilled the Risk, Injury, Failure, Loss of kidney function, and 
End-stage kidney disease (RIFLE) criteria for acute kidney 
injury.16 None of the patients had hepatic failure. All patients 
received midazolam infusion for a median time of 14 hours (8-
27 hours). Midazolam was stopped for at least 12 hours before 
the clinical assesment and the serum and urine sampling (me-
dian 36 hours, minimum time 12 hours, maximum 76 hours) 
and all concommitant sedation was interrupted for at least 3 
hours. Serum and urine midazolam levels are shown in Table 1. 
Serum midazolam levels correlated moderately with the 
GCS (R = -0.496, p = 0.026) and better with the FOUR score 
(R = -0.685, p = 0.001) but did not correlate with measured 
levels in the urine (R = -0.029, p = 0.904) even when patients 
without AKI were analysed separately (n = 12, R = 0.173, p 
= 0.572). Figure 1 presents the scatter plot of measured urine 
and serum drug levels in our population. 
d i s c u s s i o n
Our results show that serum midazolam levels correlate 
with the observed LOC in critically ill patients after discontinu-
ation of sedation, while the urine levels do not. These findings 
are in accordance with previously published work reporting 
a reasonable correlation of serum midazolam levels with the 
depth of anesthesia.5 There are also in accordance with the 
findings of Rosich Andreu et al that showed that the serum 
but not the urine benzodiazepine levels correlated moderately 
with the time to awakening, estimated as time to eye opening, 
after discontinuation of sedation in a critically ill population.17
The phenomenon of residual sedative action is the main 
reason for avoiding benzodiazepines in modern ICUs.18 Re-
sidual sedation is related to prolonged mechanical ventilation 
and ICU length of stay. Other side effects of benzodiazepines 
include delirium, agitation and withdrawal symptoms when the 
drug is discontinued. Other sedatives commonly used in in ICU 
include propofol, remifentanyl and dexmedetomidine. These 
drugs have a more attractive pharmacokinetic profile and their 
dosage can be easily titrated to the desired sedative effect. 
Nevertheless, intravenous benzodiazepines have a favourable 
hemodynamic profile and provide an acceptable option for 
sedation in patients that are hemodynamically compromised.18
when midazolam is deemed to be the sedative of choice, 
a number of strategies can be applied to avoid a prolonged 
sedative effect, such as, careful titration of dosage to the mini-
mum achieving the desired depth of sedation, a lighter level 
of sedation, combinations of midazolam with other medica-
tions and daily sedation vacation. Drug level monitoring and 
Figure 1: Scatter plot showing the correlation between serum 
and urine levels of midazolam (R = - 0.029, p = 0.904).
Table 1. Patient demographics, clinical characteristics 
and measured midazolam levels
Number of patients 20
Male / Female 10 / 10
Age (Years) 66 (20 - 90)#
Weight (Kg) 77.5 (45 - 160)#
SOFA score 8 (4 - 15)#
GCS 7 (3 - 14)#
FOUR score 10 (3 - 15)#
Reasons for ICU admission n (%)
Septic shock 7 (35%)
Respiratory failure/ARDS 7 (35%)
Acute surgery and trauma 6 (30%)
Serum midazolam levels (ng/mL) 513 (2200 - 106)#
Urine midazolam levels (ng/mL) 571 (938 - 83 )#
# Median (Minimum – Maximum)
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Table 3. The Full Outline of UnResponsiveness Score
eye Response
action Score
Opens eyes spontaneously, tracks, blinks to command 4
Opens eyes, does not track or blink to command 3
Eyes closed, open to loud voice 2
Eyes closed, open to painful stimulation 1
Eyes remain closed following painful stimulation 0
Motor Response
action Score
Obeys, makes sign e.g. “thumbs up” 4
Localises painful stimulus 3
Flexes to painful stimulus 2
Extends to painful stimulus 1
No response 0
Myoclonic Status Epilepticus 0
brainstem Reflexes
action Score
Pupils +, corneals +, cough + 4
One pupil unreactive, corneals+, cough+ 3
Pupils -, corneals +, cough NA 2
Pupils +, corneals -, cough NA 2
Pupils -, corneals -, cough + 1
Pupils -, corneals -, cough - 0
Intubation
action Score
Not intubated, normal respiration 4
Not intubated, Cheyne Stokes respiration 3
Not intubated, irregular respiration 2
Not intubated, apnoeic 0
Intubated, breathes above ventilator settings 1
Intubated, breathes below ventilator settings 0
+ = present, - = absent
electrophysiological assessment of the depth of anaesthesia 
by continuous electroencephalography or with the bispectral 
index also play a supportive role.19 
we showed that serum midazolam levels correlated moder-
ately with the GCS (R = -0.496, p = 0.026) and better with the 
FOUR score (R = -0.685, p = 0.001). In order to understand 
this finding we need to take a better look at the two methods 
for assesing the LOC in the critically ill. The GCS (Table 2) 
was originally designed for assessing head trauma severity13 and 
has become the most widely used scoring system for all patients 
with an altered level of consciousness in the ICU. Important 
limitations of the GCS are the inconsistent inter-observer 
reliability, the impossibility of assessing the verbal score in 
intubated patients, and the exclusion of brainstem reflexes. 
The FOUR score (Table 3) incorporates important informa-
tion that is not assessed by the GCS, such as the presence of 
brainstem reflexes, eye movement (blinking and tracking), a 
broad spectrum of motor responses and the pattern and rate 
of respiration, therefore, it is more suitable by design for the 
critically ill.14
we chose to evaluate our patients by using a LOC scale 
rather than a sedation scale such as the Richmond Agita-
tion–Sedation Scale (RASS).20 Sedation scales are designed 
to provide a tool for sedative titration to patient comfort and 
not for the assesment of wakefulness as a component of con-
Table 2. The Glasgow Coma Scale
behaviour Response
Eye Opening 4. Spontaneously
3. To speech
2. To pain
1. No response
Verbal 5. Oriented to time, person and place
4. Confused
3. Inappropriate words
2. Incomprehensible sounds
1. No response
Motor 6. Obeys commands
5. Moves to localized pain
4. Flexion to withdraw from pain
3. Abnormal flexion
2. Abnormal extension
1. No response
sciousness. However, our results show that residual sedation 
effects were present in many of our patients who had high 
serum midazolam levels. 
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The lack of correlation between urine and serum mida-
zolam levels is not surprising given the pharmacokinetics 
of the drug. Midazolam has a two compartment model of 
distribution and elimination that can become a three com-
partment model when the drug is administered by continuous 
infusion for a prolonged period of time.21 Pharmacokinetic 
two-compartment models divide the body into a central and 
a peripheral compartment. The central compartment consists 
of the plasma and tissues where the distribution of the drug is 
practically instantaneous. The peripheral compartment con-
sists of tissues where the distribution of the drug is slower. A 
third compartment is relevant when highly and poorly perfused 
tissues participate in the model. In multiple compartment phar-
macokinetics, phenomena of redistribution take place.22 These 
may interfere with the serum levels of the drug and its rate 
of elimination and explain why urine levels do not correlate 
with serum levels even when the former are corrected for the 
creatinine clearance, the serum albumin or the liver function.
Our study has some limitations that need to be taken into 
account when interpreting the results. Firstly, the sample size 
is small. Limited resources did not allow us to have a sample 
large enough to identify a subpopulation in which urine levels 
could possibly correlate better with the serum levels and the 
LOC. Such a subpopulation could theoretically be the healthier 
patients who received a smaller total dose of the drug. A 
larger sample would also allow us to obtain measurements 
from patients with prolonged infusions. Another limitation 
is that the biochemical methods for midazolam estimation in 
the serum and in the urine were both semiquantitative rather 
than quantitative, and this means lower precision.23,24 One may 
argue that the lack of precision is a reason for not identifying 
a correlation between urine levels and the LOC, however we 
think that this is unlikely, based on both previous work and 
on the models of benzodiazepine pharmacokinetics.17,21 In 
the present study we did not perform serial measurements of 
midazolam levels and did not observe the patients long enough 
to identify a correlation of drug levels with the awakening pro-
cess and the disease severity. Estimating the effect of disease 
severity to the awakening time is difficult to assess since the 
GCS is inherent to the SOFA score. Although finding a cor-
relation between disease severity and time to awaken was not 
the aim of our study, it would definitely be of clinical value. 
Another limitation is that some patients were on CVVHDF 
for renal failure. There is a known effect of kidney injury on 
the pharmacokinetics of midazolam that may affect drug levels. 
However, when samples from patients without kidney injury 
are examined seperately (Figure 1) there is still no significant 
correlation between serum and urine midazolam levels. Lastly, 
a number of patients received propofol for sedation. The drug 
was discontinued for at least three hours before the sampling 
and due to its short time of action we believe that it had little 
or no effect in the measured LOC. 
In conclusion, serum midazolam levels correlate with 
the LOC particularly as estimated by the FOUR score in the 
critically ill , and can therefore provide a useful tool for the dif-
ferential diagnosis in patients who are slow to wake following 
discontinuation of sedation. Urine midazolam levels, at least 
as a single measurement are not correlated with the LOC and 
can not help in the discrimination of residual sedation from 
other causes of coma. Intensivists need to take into account a 
possible unwanted prolonged sedative action when choosing 
midazolam to sedate their patients, should titrate midazolam 
infusion with caution and reside in this drug when newer seda-
tives with faster elimination are contraindicated. 
r e F e r e n c e s
1. Brunton L, Chabner B, Knollman B, et al. The Pharmacologi-
cal Basis of Therapeutics 12th ed. McGraw Hill, New York, 
NY, 2011.
2. Arcangeli A, Antonelli M, Mignani V, et al. Sedation in PACU: 
the role of benzodiazepines. Current Drug Targets 2005; 
6:745–748. doi:10.2174/138945005774574416.
3. Riss J, Cloyd J, Gates J et al. Benzodiazepines in epilepsy: phar-
macology and pharmacokinetics. Acta Neurologica Scandinavi-
ca 2008; 118:69–86. doi:10.1111/j.1600-0404.2008.01004.x. 
4. Heizmann P, Eckert M, Ziegler WH. Pharmacokinetics and 
bioavailability of midazolam in man. Br J clin Pharmac 1983; 
16:43S-49S.
5. Persson P, Nilsson A, Hartvig P et al. Pharmacokinetics of mi-
dazolam in total iv anaesthesia. Br J Anaesth 1987; 59:548-556.
6. O’Connor M, Bucknall T, Manias E. Sedation management in 
Australian and New Zealand intensive care units: doctors’ and 
nurses’ practices and opinions. American Journal of Critical 
Care 2010; 19:285–295. doi:10.4037/ajcc2009541
7. Tse AHW, Ling L, Lee A, et al. Altered Pharmacokinetics 
in Prolonged Infusions of Sedatives and Analgesics Among 
Adult Critically Ill Patients: A Systematic Review. Clin Ther 
2018; 40:1598-1615.e2. doi: 10.1016/j.clinthera.2018.07.021
8. Horsting MW, Franken MD, Meulenbelt J et al. The etiology 
and outcome of non-traumatic coma in critical care: a sys-
tematic review. BMC Anesthesiol 2015; 15:65. doi: 10.1186/
s12871-015-0041-9.
9. Weiss N, Regard L, Vidal C et al. Causes of coma and their 
evolution in the medical intensive care unit. J Neurol 2012; 
259:1474-1477. doi: 10.1007/s00415-011-6388-z.
10. McKenzie CA, McKinnon W, Naughton DP, et al. Differentiat-
ing midazolam over-sedation from neurological damage in the 
intensive care unit. Crit Care 2005; 9:R32-6. 
11. Melanson SE. The utility of immunoassays for urine drug 
testing. Clin Lab Med 2012; 32:429-447. 
12. Smydo J. Delayed respiratory depression with fentanyl. Anes-
thesia Progress 1979; 26:47–48.
13. Teasdale G, Jennett B. Assessment of coma and impaired 
consciousness. A practical scale. Lancet 1974; 304:81–84. 
doi:10.1016/S0140-6736(74)91639-0.
CORRELATION OF SERUM AND URINE MIDAzOLAM LEVELS wITH CONSCIOUSNESS TESTS
53
14. Wijdicks EF, Bamlet WR, Maramattom BV et al. Valida-
tion of a new coma scale: The FOUR score. Ann Neurol 
2005;58:585-593.
15. Vincent JL, de Mendonça A, Cantraine F et al. Use of the SOFA 
score to assess the incidence of organ dysfunction/failure in 
intensive care units: results of a multicenter, prospective study. 
Working group on “sepsis-related problems” of the European 
Society of Intensive Care Medicine. Crit Care Med 1998; 
26:1793-1800.
16. Lopes JA, Jorge S. The RIFLE and AKIN classifications for 
acute kidney injury: a critical and comprehensive review. 
Clinical Kidney Journal 2013; 6:8–14. doi:10.1093/ckj/sfs160.
17. Rosich Andreu SR, Moreno Muñoz G, Marin Corral J, et al. 
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